It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with two PharmaLex experts about navigating complex R&D ...

Angels for Change (A4C) announces the pilot launch of Project GOLD (Generic Oncology Lifesaving Drugs), a new resiliency program that establishes an onshore buffer supply of six essential medications ...

Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $300 million, “primarily for debt paydown and general corporate purposes,” the company said ...

Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $50 million in ...

Walgreens is offloading more shares in drug distributor Cencora as the struggling pharmacy chain looks to generate cash. The latest sale netted about $300 million for Walgreens, and shrinks the ...

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount ...

(Reuters) - U.S. drugstore chain Walgreens Boots Alliance said on Thursday it has sold more shares in drug distributor Cencora for proceeds of about $300 million. The company said that it now owns a 6 ...

Cencora assumes no obligation to update any ... leadership in specialty in a high-growth pharmaceutical-centric segment building on our services for our customers and positioning us well in ...

Cencora (COR) has significantly expanded the number and type of medications available in its sure supply program, a drug shortage mitigation initiative designed to provide health systems with ...

Marks significant expansion of initiative to help health systems access critical, at-risk medications for patients Cencora, a global healthcare company, has significantly expanded the number and ...

Full Year Operating Income Growth Guidance: 11.5% to 13.5%. Cencora Inc (NYSE:COR) reported a strong start to fiscal year 2025 with a 13% increase in revenue and a 14% growth in adjusted EPS.